Abstract
Purpose: To investigate the protective effect of liraglutide on myocardial ischemia reperfusion (I/R) injury and its molecular mechanism. Methods: Ischemia reperfusion model male Sprague-Dawley (SD) rats were randomly divided into negative control group, I/R group (saline), liraglutide group (liraglutide) and PD group (liraglutide + PD98059). The weight of myocardium in ischemic and infarction areas of the heart, myocardial injury biomarker, oxidative stress, as well as expressions of mRNA molecules of apoptosis were determined. Results: The myocardial mass of ischemic and infarcted areas of the heart (relative to left ventricular mass) of I/R group were significantly higher ( p ˂ 0.05) than those of negative control group, but significantly lower in liraglutide group than in I/R group ( p > 0.05). However, the parameters were significantly higher in PD group than in liraglutide group ( p ˂ 0.05). CK, CK-MB and LDH activities, as well as levels of cTnI and cTnT in I/R group were significantly higher ( p ˂ 0.05) than those of negative control group. However, the parameters were significantly lower ( p ˂ 0.05) in liraglutide group than in I/R group, but higher in PD group ( p ˂ 0.05) than in liraglutide group. Serum SOD, GSH-Px, CAT activities and tBcl-2 mRNA expression were significantly lower in I/R group than those of negative control group ( p ˂ 0.001), while those PD group were significantly lower than those of liraglutide group ( p ˂ 0.001). Conclusion: Liraglutide alleviates myocardial ischemia-reperfusion injury and inhibits oxidative stress and apoptosis via ERK1/2 signaling pathway in rats, but further studies are required to ascertain the clinical efficacy and safety of the compound. Keywords: Ischemia-reperfusion injury, Liraglutide, ERK1/2 signal pathway, Oxidative stress, Apoptosis
Highlights
Myocardial ischemia reperfusion (IR) injury refers to the pathophysiological process of aggravated injury after ischemic myocardial perfusion
Myocardial mass of ischemic and infarcted areas, and percentages of each of these parameters relative to left ventricular mass of the ischemia reperfusion (I/R) group were significantly higher (p 0.05) than those of negative control group. These parameters were significantly lower in the liraglutide group than in the I/R group (p > 0.05), but were significantly higher in the PD group when compared with the liraglutide group (p 0.05)
In order to investigate whether liraglutide has protective effect on myocardial I/R injury in rats, myocardial ischemia and infarcted were analyzed in this study
Summary
Myocardial ischemia reperfusion (IR) injury refers to the pathophysiological process of aggravated injury after ischemic myocardial perfusion. Reduction of myocardial IR injury is an important objective in improvement of reperfusion in patients with myocardial infarction [1,2,3]. Liraglutide is a new drug that has been used for type 2 diabetes in recent years It is a glucagon-like peptide l (GLP-1) analogue, which effectively reduces blood glucose levels, regulates blood lipid metabolism and relieves insulin resistance in Type 2 diabetes. Recent studies have reported that liraglutide regulates glucolipid metabolism, and improves endothelial and myocardial cell functions. It reduces myocardial cell injury caused by hypoxia and hypoxia re-oxygenation conditions [4,5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
